Glaukos is an ophthalmic pharmaceutical and medical device company that develops novel therapies for glaucoma, corneal disorders, and retinal disease. The company's core products include the iStent family of micro-invasive glaucoma surgery devices that restore natural drainage in the eye, iDose TR, an intracameral pharmaceutical delivering continuous medication within the eye, the iLink platform for corneal cross-linking therapies, and pipeline products including transdermal and intravitreal formulations. Glaukos sells primarily to ambulatory surgery centers, hospitals, and physician practices, generating revenue through product sales reimbursed by Medicare, commercial insurers, Medicaid, and international payers, with the vast majority of revenue derived from glaucoma products.